Functional reprogramming of regulatory T cells in the absence of Foxp3

Louis-Marie Charbonnier,Ye Cui,Emmanuel Stephen-Victor,Hani Harb,David Lopez,Jack J. Bleesing,Maria I. Garcia-Lloret,Karin Chen,Ahmet Ozen,Peter Carmeliet,Ming O. Li,Matteo Pellegrini,Talal A. Chatila,Louis-Marie Charbonnier,Ye Cui,Emmanuel Stephen-Victor,Hani Harb,David Lopez,Jack J. Bleesing,Maria I. Garcia-Lloret,Karin Chen,Ahmet Ozen,Peter Carmeliet,Ming O. Li,Matteo Pellegrini,Talal A. Chatila
DOI: https://doi.org/10.1038/s41590-019-0442-x
IF: 30.5
2019-08-05
Nature Immunology
Abstract:Regulatory T cells (T<sub>reg</sub> cells) deficient in the transcription factor Foxp3 lack suppressor function and manifest an effector T (T<sub>eff</sub>) cell–like phenotype. We demonstrate that Foxp3 deficiency dysregulates metabolic checkpoint kinase mammalian target of rapamycin (mTOR) complex 2 (mTORC2) signaling and gives rise to augmented aerobic glycolysis and oxidative phosphorylation. Specific deletion of the mTORC2 adaptor gene <i>Rictor</i> in Foxp3-deficient T<sub>reg</sub> cells ameliorated disease in a Foxo1 transcription factor–dependent manner. Rictor deficiency re-established a subset of T<sub>reg</sub> cell genetic circuits and suppressed the T<sub>eff</sub> cell–like glycolytic and respiratory programs, which contributed to immune dysregulation. Treatment of T<sub>reg</sub> cells from patients with FOXP3 deficiency with mTOR inhibitors similarly antagonized their T<sub>eff</sub> cell–like program and restored suppressive function. Thus, regulatory function can be re-established in Foxp3-deficient T<sub>reg</sub> cells by targeting their metabolic pathways, providing opportunities to restore tolerance in T<sub>reg</sub> cell disorders.
immunology
What problem does this paper attempt to address?